Rize Oncology Inc.
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.33% | -81.23% | -127.17% | -73.15% | -62.03% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.88% | 98.96% | 261.76% | -85.74% | -71.15% |
| Change in Net Operating Assets | 622.47% | -17.31% | -341.18% | -23.72% | -117.12% |
| Cash from Operations | 30.28% | -30.50% | -125.82% | -189.47% | -158.35% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.73% | 2.73% | 2.73% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.37% | 2.73% | 2.73% | -- | -- |
| Foreign Exchange rate Adjustments | 52.38% | 207.62% | 163.37% | 66.67% | 104.56% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.62% | -62.44% | -304.71% | -105.97% | -41.85% |